Audhya Paul K. reported option exercise involving 5,000 shares of KalVista Pharmaceuticals, Inc. on May 22, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
CHIEF MEDICAL OFFICER
CHIEF MEDICAL OFFICER
Filed May 27, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
5,000Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
152,499Direct
Trade date
May 22, 2026Option exercise
Filed
May 27, 2026, 4:05 PM ET5-day reporting delay
Accession
0001860131-26-000008Code M · Transaction 87103
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Option exercise5,000$0.00$0Trade 87105
May 26, 2026Sell2,239$26.78−$59,955.49Trade 87104
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

KALV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KALV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −27%1w ago −0.2%1d ago −0.1%
Returns since7d +0.6%30d +0.8%90d +0.8%180d1y

Footnotes in full

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: 1/16th of the total restricted stock units subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 22, 2024, subject to continued service through each vesting date.